BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 21242970)

  • 1. Targeting the Akt/mTOR pathway in Brca1-deficient cancers.
    Xiang T; Jia Y; Sherris D; Li S; Wang H; Lu D; Yang Q
    Oncogene; 2011 May; 30(21):2443-50. PubMed ID: 21242970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative Regulation of AKT Activation by BRCA1.
    Xiang T; Ohashi A; Huang Y; Pandita TK; Ludwig T; Powell SN; Yang Q
    Cancer Res; 2008 Dec; 68(24):10040-4. PubMed ID: 19074868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Akt1 inhibits homologous recombination in Brca1-deficient cells by blocking the Chk1-Rad51 pathway.
    Jia Y; Song W; Zhang F; Yan J; Yang Q
    Oncogene; 2013 Apr; 32(15):1943-9. PubMed ID: 22665067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
    Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
    Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
    Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
    Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma.
    Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z
    BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
    Castillo-Pichardo L; Dharmawardhane SF
    Nutr Cancer; 2012; 64(7):1058-69. PubMed ID: 23061908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.
    You S; Li W; Guan Y
    Mol Med Rep; 2018 Mar; 17(3):4203-4212. PubMed ID: 29344654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling.
    Chen Y; Wei H; Liu F; Guan JL
    J Biol Chem; 2014 Jan; 289(2):1164-73. PubMed ID: 24275666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.
    Bai F; Liu S; Liu X; Hollern DP; Scott A; Wang C; Zhang L; Fan C; Fu L; Perou CM; Zhu WG; Pei XH
    Breast Cancer Res; 2021 Jan; 23(1):10. PubMed ID: 33478572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
    Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways.
    Pratheeshkumar P; Budhraja A; Son YO; Wang X; Zhang Z; Ding S; Wang L; Hitron A; Lee JC; Xu M; Chen G; Luo J; Shi X
    PLoS One; 2012; 7(10):e47516. PubMed ID: 23094058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
    Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
    Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001.
    De Angel RE; Conti CJ; Wheatley KE; Brenner AJ; Otto G; Degraffenried LA; Hursting SD
    Mol Carcinog; 2013 Jun; 52(6):446-58. PubMed ID: 22290600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
    Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction.
    Jia L; Huang S; Yin X; Zan Y; Guo Y; Han L
    Life Sci; 2018 Sep; 208():123-130. PubMed ID: 30025823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.